Company: SHPH
Filing Date: 2025-05-15
Form Type: 8-K
Source: 0001641172-25-010964
Chunk: 2

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-05-15
Form: 8-K
Item: Item 5.07
Chunk 2
---
      Against                                Non-Votes  
 ───────────────────────────────────────────────────────────────────
  2,771,322      240,834                    87,461      1,078,407  

A
majority of the shares present in person or by proxy and entitled to vote at the Meeting was required for approval. Accordingly, Proposal
6 was approved.

Proposal
No. 7: approval of the issuance of more than 20% of our common stock upon the offering, sale and subsequent conversion of convertible
preferred stock or common stock in accordance with Nasdaq Listing Rule 5635(d).

      Votes        Votes      Abstentions/Withheld         Broker  
        For      Against                                Non-Votes  
 ───────────────────────────────────────────────────────────────────
  2,545,615      182,894                   371,108      1,078,407  

A
majority of the shares present in person or by proxy and entitled to vote at the Meeting was required for approval. Accordingly, Proposal
7 was approved.

Proposal
No. 8: Approval of the issuance of more than 20% of our common stock upon the issuance of common stock under a planned equity line of
credit agreement in accordance with NASDAQ Listing Rule 5635(d).

      Votes        Votes      Abstentions/Withheld         Broker  
        For      Against                                Non-Votes  
 ───────────────────────────────────────────────────────────────────
  2,549,850      388,450                   161,317      1,078,407  

A
majority of the shares present in person or by proxy and entitled to vote at the Meeting was required for approval. Accordingly, Proposal
8 was approved.

   3  

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

  SHUTTLE PHARMACEUTICALS HOLDINGS, INC.                                       
  Dated: May 15, 2025                                                          
  By:                                         /s/ Christopher Cooper           
  Name:                                       Christopher Cooper               
  Title:                                      Interim Chief Executive Officer  

   4